← Eichor
Study identifier: NCT07496086 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

External Oblique Intercostal Block Versus Transversus Abdominis Plane Combined With Rectus Sheath Block on Postoperative Pain in Laparoscopic Radical Gastrectomy

Condition: Postoperative Pain  ·  Sponsor: General Hospital of Ningxia Medical University

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Postoperative pain is highly prevalent following laparoscopic radical gastrectomy. Although Transversus abdominis plane block combined with rectus sheath block(TAP+RSB) can effectively alleviate this pain, it still has many limitations. The external oblique intercostal plane block (EOIB) is a novel nerve block technique that may provide well postoperative analgesia for upper abdominal surgery. Therefore, this study employs a non-inferiority randomized controlled trial design to verify that the analgesic effect of EOIB is not inferior to that of ESPB, thereby offering more options for regional analgesia strategies in laparoscopic radical gastrectomy.

This description comes directly from the study's public registry record.

Talk to the study team

lingzi Yin, Doctoral  ·  86-951-674-3252  ·  eleven87670@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

General hospital of Ningxia medical universityYinchuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07496086